Vaxcyte, Inc.
PCVX
Ранг среди акций
#2080
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage,... Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
Цена акции
$64.29
Последняя синхронизация: 2026-10-19
Рыночная капитализация
$9.86B
Изменение (1 день)
1.05%
Изменение (1 год)
49.86%
Страна
US
Торговля Vaxcyte, Inc. (PCVX)
Категория
Healthcare
Коэффициент P/B для Vaxcyte, Inc. (PCVX)
Коэффициент P/B на October 2026 TTM: 3.54
Согласно последним финансовым отчетам и цене акций Vaxcyte, Inc., текущий коэффициент P/B (TTM) составляет 3.54. В конце 2023 он составлял 4.92.
История P/B для Vaxcyte, Inc. с 2017 по 2026
Коэффициент P/B в конце каждого года
| Год | P/B | Изменить |
|---|---|---|
| 2026 (TTM) | 3.54 | 17.19% |
| 2024 | 3.02 | -38.58% |
| 2023 | 4.92 | 50.78% |
| 2022 | 3.26 | -24.99% |
| 2021 | 4.35 | 91.61% |
| 2020 | 2.27 | -343.31% |
| 2019 | -0.93 | -43.25% |
| 2018 | -1.64 | -154.55% |
| 2017 | 3.01 | 0.00% |
Коэффициент P/B для аналогичных компаний или конкурентов
| Компания | P/B | Разница P/B | Страна |
|---|---|---|---|
| 6.251 | 76.63% |
US
|
|
| 13.2547 | 274.52% |
US
|
|
| 4.208 | 18.90% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | 74.69% |
NL
|
